Comparison of gene expression profiles between de novo CD5+ DLBCLs and CD5- DLBCLs shows that de novo CD5+ DLBCL expresses high levels of integrin beta1 in tumor cells and CD36 in the vascular cells.
In contrast, CD36 was overexpressed on vascular endothelia in CD5(+) DLBCLs, although there was no difference in vascularity detected by von Wilbrand factor antibody between CD5(+) and CD5(-) DLBCLs.